Access primary patency |
Interval of time from AV dialysis access creation to the first of one of the following events: access thrombosis; any intervention designed to facilitate, maintain, or re-establish patency; the access reaches a censoring event as specified a priori in the study protocol; or study end. |
Access assisted primary patency |
Interval of time from AV dialysis access creation until the first of one of the following events: access thrombosis, the access reaches a censoring event as specified a priori in the study protocol, or study end. This period includes all intervening interventions (surgical or endovascular) designed to maintain the functionality of the dialysis vascular access as long as patency is not lost. |
Access cumulative patency* |
Interval of time from AV dialysis access creation until access abandonment, the access reaches a censoring event as specified a priori in the study protocol, or study end, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of the access. |
Post-intervention¶ primary patency |
The interval of time from the index IDBD until the first of one of the following events: access thrombosis; any intervention designed to facilitate, maintain, or re-establish patency; the access reaches a censoring event as specified a priori in the study protocol; or study end. |
Post-intervention¶ assisted primary patency |
The interval of time from the index IDBD intervention to the first of one of the following events: access thrombosis, a surgical intervention that excludes the treated lesion from the dialysis access circuit, or the patient reaches a censored event as defined a priori in the study protocol. This period includes all intervening interventions (surgical or endovascular) designed to maintain the functionality of dialysis vascular access. |
Post-intervention¶ cumulative patency* |
The interval of time from the index IDBD intervention until the access is abandoned, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of a patent access, the patient reaches a censoring event as defined a priori in the study protocol, or study end. |
Do you want to add Medilib to your home screen?